Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ocular Therapeutix (OCUL) Other Non-Current Assets (2016 - 2026)

Ocular Therapeutix has reported Other Non-Current Assets over the past 14 years, most recently at $1.6 million for Q1 2026.

  • For Q1 2026, Other Non-Current Assets changed 0.0% year-over-year to $1.6 million; the TTM value through Mar 2026 reached $1.6 million, changed 0.0%, while the annual FY2025 figure was $1.6 million, 0.0% changed from the prior year.
  • Other Non-Current Assets for Q1 2026 was $1.6 million at Ocular Therapeutix, roughly flat from $1.6 million in the prior quarter.
  • Over five years, Other Non-Current Assets peaked at $1.8 million in Q1 2022 and troughed at $1.6 million in Q4 2023.
  • A 5-year average of $1.7 million and a median of $1.6 million in 2023 define the central range for Other Non-Current Assets.
  • Biggest five-year swings in Other Non-Current Assets: changed 0.0% in 2022 and later decreased 8.5% in 2023.
  • Year by year, Other Non-Current Assets stood at $1.8 million in 2022, then decreased by 8.5% to $1.6 million in 2023, then changed by 0.0% to $1.6 million in 2024, then changed by 0.0% to $1.6 million in 2025, then changed by 0.0% to $1.6 million in 2026.
  • Business Quant data shows Other Non-Current Assets for OCUL at $1.6 million in Q1 2026, $1.6 million in Q4 2025, and $1.6 million in Q3 2025.